Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment.
Smith EA, Belote RL, Cruz NM, Moustafa TE, Becker CA, Jiang A, Alizada S, Chan TY, Seasor TA, Balatico M, Cortes-Sanchez E, Lum DH, Hyngstrom JR, Zeng H, Deacon DC, Grossmann AH, White RM, Zangle TA, Judson-Torres RL.
Smith EA, et al. Among authors: zangle ta.
bioRxiv [Preprint]. 2024 Jun 17:2024.06.15.599116. doi: 10.1101/2024.06.15.599116.
bioRxiv. 2024.
PMID: 38948879
Free PMC article.
Preprint.